Compare CBSH & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBSH | IMVT |
|---|---|---|
| Founded | 1865 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 8.0B |
| IPO Year | 2008 | 2019 |
| Metric | CBSH | IMVT |
|---|---|---|
| Price | $59.09 | $40.62 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $58.28 | $33.00 |
| AVG Volume (30 Days) | ★ 1.2M | 1.0M |
| Earning Date | 04-21-2026 | 05-28-2026 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | ★ 4.39 | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.43 | N/A |
| Revenue Next Year | $3.43 | N/A |
| P/E Ratio | $61.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $46.99 | $14.32 |
| 52 Week High | $63.49 | $41.23 |
| Indicator | CBSH | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 63.11 | 62.17 |
| Support Level | $51.97 | $37.53 |
| Resistance Level | $59.27 | $41.22 |
| Average True Range (ATR) | 0.99 | 1.39 |
| MACD | -0.14 | -0.26 |
| Stochastic Oscillator | 57.12 | 75.68 |
Commerce Bancshares Inc operates as the bank holding company for Commerce Bank. The bank is engaged in the general banking business, providing a broad range of retail, mortgage banking, corporate, investment, trust, and asset management products and services to individuals, businesses, and municipalities. The company has three reportable segments. The Commercial segment provides lending, leasing, deposit, payment, and cash management services to business and government customers. The Retail Banking segment offers consumer deposits, consumer lending, mortgage banking, and debit and credit card services through its branch network. The Wealth segment provides trust, estate planning, brokerage, and investment management services to individual and institutional clients.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.